<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>DIGIFAB- ovine digoxin immune fab injection, powder, for solution </strong><br>BTG International Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer"><span class="Bold">These highlights do not include all the information needed to use DIGIFAB safely and effectively.  See full prescribing information for DIGIFAB<span class="Sup">®</span>. 
			<br><br>DigiFab<span class="Sup">®</span>, Digoxin Immune Fab (Ovine) For Intravenous Injection Only – Lyophilized Powder for Solution
			<br>IInitial U.S. Approval: 2001
		</span></div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><p class="Highlighta">DigiFab<span class="Sup">®</span> is a digoxin immune fab (ovine) and is indicated for treatment of life-threatening or potentially life-threatening <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">digoxin toxicity</span> or <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>.   (<a href="#section-1">1</a>)</p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div>
<p class="Highlighta">For intravenous use only  (<a href="#section-2">2</a>)</p>
<table class="Noautorules">
<col width="45%">
<col width="55%">
<tbody class="Headless">
<tr>
<td>Clinical Conditions</td>
<td>Dosage</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><span class="Bold">Acute ingestion of unknown amounts of digoxin and toxicity in the absence of a serum digitalis concentration or estimated ingestion amount</span></td>
<td class="Botrule Lrule Rrule Toprule">Administer 20 vials of DigiFab<span class="Sup">®</span>.<br>Monitor for volume overload in small (&lt; 20 Kg) children.<br>Start with 10 vials followed by an additional 10 vials, if needed, to avoid a <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">febrile reaction</span>.
											</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><span class="Bold">Chronic <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">digoxin toxicity</span> in the absence of a serum digitalis concentration</span></td>
<td class="Botrule Lrule Rrule">Administer 6 vials of DigiFab<span class="Sup">®</span> in Adults and Children ≥ 20 Kg.<br>Administer 1 vial of DigiFab<span class="Sup">®</span> in Infants and Children &lt; 20 Kg.
											</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><span class="Bold">Acute ingestion of known amounts of digoxin</span></td>
<td class="Botrule Lrule Rrule">Dose (in vials) = <br><span class="Underline">Amount of digoxin ingested (in mg)</span><br>            0.5 mg/vial</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><span class="Bold">Chronic <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">digoxin toxicity</span> and known serum digitalis concentration</span></td>
<td class="Botrule Lrule Rrule Toprule">Dose (in vials) = <br><span class="Underline">(Serum digoxin ng/mL)(weight in kg)</span><br>            100</td>
</tr>
</tbody>
</table>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">DigiFab<span class="Sup">®</span> is supplied as a sterile, lyophilized preparation. Each vial contains 40 mg of digoxin immune fab protein.  (<a href="#section-3">3</a>)</p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><p class="Highlighta">There are no known contraindications.  (<a href="#section-4">4</a>)</p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul>
<li>Rapid drop in serum potassium concentration after treatment with DigiFab<span class="Sup">®</span>.   Monitor frequently, especially after the first several hours of DigiFab administration. (<a href="#AS051">5.1</a>)
									</li>
<li><span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylaxis</span> and <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> are possible.  Patients with allergies to papain, chymopapain, other papaya extracts, or the pineapple enzyme bromelain may be at risk for an <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> to DigiFab<span class="Sup">®</span>. (<a href="#AS052">5.2</a>)
									</li>
<li>Clinically misleading reading of standard serum digoxin concentration may occur after administration of DigiFab<span class="Sup">®</span> due to interference with digitalis immunoassay measurements. (<a href="#AS054">5.4</a>)
									</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">The most common adverse reactions (&gt;7%) are worsening <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> (13%), <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> (13%) and worsening <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span> (7%). (<a href="#AS060">6</a>) </p>
<br><p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact BTG 1-877-377-3784, or FDA at 1-800-FDA-1088 or <span class="Italics Underline">www.fda.gov/medwatch.</span></span> </p>
</div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><ul><li>Pregnancy: No human or animal data. Use only if clearly needed. (<a href="#AS081">8.1</a>)</li></ul></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 1/2012</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1  INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2  DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1  Dosage</a></h2>
<h2><a href="#section-2.2" class="toc">2.2  Preparation and Administration</a></h2>
<h1><a href="#section-3" class="toc">3  DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4  CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5  WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 General</a></h2>
<h2><a href="#section-5.2" class="toc">5.2 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span></a></h2>
<h2><a href="#section-5.3" class="toc">5.3 Use of DigiFab<span class="Sup">®</span> in <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal Failure</span></a></h2>
<h2><a href="#section-5.4" class="toc">5.4 Laboratory Tests</a></h2>
<h1><a href="#section-6" class="toc">6  ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trial Experience</a></h2>
<h1><a href="#section-7" class="toc">8  USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-7.1" class="toc">8.1  Pregnancy</a></h2>
<h2><a href="#section-7.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-7.3" class="toc">8.4  Pediatric Use</a></h2>
<h2><a href="#section-7.4" class="toc">8.5  Geriatric Use</a></h2>
<h1><a href="#section-8" class="toc">11  DESCRIPTION</a></h1>
<h1><a href="#section-9" class="toc">12  CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-9.1" class="toc">12.1  Mechanism of Action</a></h2>
<h2><a href="#section-9.2" class="toc">12.3  Pharmacokinetics</a></h2>
<h1><a href="#section-10" class="toc">13  NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-10.1" class="toc">13.1  Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h2><a href="#section-10.2" class="toc">13.2 Animal Toxicology and/or Pharmacology</a></h2>
<h1><a href="#section-11" class="toc">14  CLINICAL STUDIES</a></h1>
<h1><a href="#section-12" class="toc">15  REFERENCES</a></h1>
<h1><a href="#section-13" class="toc">16  HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-14" class="toc">17  PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="AS010"></a><a name="section-1"></a><p></p>
<h1>1  INDICATIONS AND USAGE</h1>
<p class="First">DigiFab<span class="Sup">®</span> is indicated for the treatment of patients with life-threatening or potentially life-threatening <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">digoxin toxicity</span> or <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, including:</p>
<ul class="Disc">
<li>Known suicidal or accidental consumption of fatal doses of digoxin: 10 mg or more of digoxin in healthy adults, or 4 mg (or more than 0.1 mg/kg) in healthy children, or ingestion of an amount that can cause steady state serum concentrations  of ≥10 ng/mL; </li>
<li>Chronic ingestions  causing steady-state serum digoxin concentrations &gt;6 ng/mL in adults or 4 ng/mL in children; </li>
<li>Manifestations of life-threatening toxicity of digoxin <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> such as severe <span class="product-label-link" type="condition" conceptid="4185572" conceptname="Ventricular arrhythmia">ventricular arrhythmias</span>, progressive <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, and second or third degree <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">heart block</span> not responsive to atropine, serum potassium levels exceeding 5.5 mEq/L in adults or 6 mEq/L in children with rapidly progressive signs and symptoms of <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">digoxin toxicity</span>. </li>
</ul>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="AS020"></a><a name="section-2"></a><p></p>
<h1>2  DOSAGE AND ADMINISTRATION</h1>
<p class="First"><span class="Bold">For Intravenous Use Only </span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="AS021"></a><a name="section-2.1"></a><p></p>
<h2>2.1  Dosage</h2>
<p class="First"><span class="Bold">General Guidelines:</span></p>
<p>Adjust the dosage of DigiFab<span class="Sup">®</span> according to the amount of digoxin to be neutralized.</p>
<table class="Noautorules" width="550">
<col width="45%">
<col width="55%">
<tbody class="Headless">
<tr><td><span class="Bold">Summary of Dosing Guidelines</span></td></tr>
<tr>
<td>Clinical Conditions</td>
<td>Dosage</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><span class="Bold">Acute ingestion of unknown amounts of digoxin and toxicity in the absence of a serum digitalis concentration or estimated ingestion amount</span></td>
<td class="Botrule Lrule Rrule Toprule">Administer 20 vials of DigiFab<span class="Sup">®</span>.<br>Monitor for volume overload in small (&lt; 20 Kg) children.<br>Start with 10 vials followed by an additional 10 vials, if needed, to avoid a <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">febrile reaction</span>.
											</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><span class="Bold">Chronic <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">digoxin toxicity</span> in the absence of a serum digitalis concentration</span></td>
<td class="Botrule Lrule Rrule">Administer 6 vials of DigiFab<span class="Sup">®</span> in Adults and Children ≥ 20 Kg.<br>Administer 1 vial of DigiFab<span class="Sup">®</span> in Infants and Children &lt; 20 Kg.
											</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><span class="Bold">Acute ingestion of known amounts of digoxin</span></td>
<td class="Botrule Lrule Rrule">Dose (in vials) = <br><span class="Underline">Amount of digoxin ingested (in mg)</span><br>            0.5 mg/vial</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><span class="Bold">Chronic <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">digoxin toxicity</span> and known serum digitalis concentration</span></td>
<td class="Botrule Lrule Rrule Toprule">Dose (in vials) = <br><span class="Underline">(Serum digoxin ng/mL)(weight in kg)</span><br>            100</td>
</tr>
</tbody>
</table>
<p>Failure of the patient to respond to DigiFab<span class="Sup">®</span> should alert the physician to the possibility that the clinical problem may not be caused by <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">digitalis toxicity</span>.</p>
<p><span class="Bold">DOSAGE CALCULATION</span></p>
<p><span class="Bold">General</span></p>
<p>Methods for calculating a neutralizing dose of DigiFab<span class="Sup">®</span>, based on a known or estimated amount of digoxin or digitoxin in the body, are provided below. When using the dose calculation methods provided, the following guidelines should be considered:</p>
<ul class="Disc">
<li>Inaccurate estimates of the amount of digitalis ingested or absorbed may occur due to non-steady state serum concentrations or due to digitalis assay limitations. Most serum digoxin assay kits are designed to measure concentrations less than 5 ng/mL; therefore, sample dilution is required to accurately measure serum concentrations &gt; 5 ng/mL.</li>
<li>Dosage calculations are based on a steady state volume of distribution of approximately 5 L/kg for digoxin, which is used to convert serum digoxin concentrations to total body burden of digoxin in milligrams. The volume of distribution is a population average and may vary among individuals. Many patients may require higher doses for complete neutralization and doses should usually be rounded up to the nearest whole vial. </li>
<li>If toxicity has not adequately reversed after several hours, or appears to recur, re-administration of DigiFab<span class="Sup">®</span>, at a dose guided by clinical judgment, may be necessary. If a patient is in need of re-administration of DigiFab<span class="Sup">®</span> due to recurrent toxicity, or to a new toxic episode that occurs soon after the first episode, measurement of free (unbound) serum digitalis concentrations should be considered since Fab may still be present in the body.</li>
<li>Failure of a patient to respond to DigiFab<span class="Sup">®</span> treatment may indicate that the clinical problem is not caused by <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">digitalis intoxication</span>. If there is no response to an adequate dose of DigiFab<span class="Sup">®</span>, the diagnosis of <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">digitalis toxicity</span> should be questioned.</li>
</ul>
<p><span class="Bold">Calculation for Ingestion of Known Amount:</span></p>
<ul class="Disc">
<li>Each vial of DigiFab<span class="Sup">®</span> (40 mg of purified digoxin-specific Fab) binds approximately 0.5 mg of digoxin.</li>
<li>The total number of vials required can be calculated by dividing the total body load of digoxin in milligrams (mg) by 0.5 mg per vial (see <a href="#F1">Formula 1</a>).</li>
<li>Following an acute ingestion, total body load will be approximately equal to the amount ingested in milligrams for either digoxin capsules or digitoxin.</li>
<li>In case of digoxin tablet ingestion , the total body load will be approximately equal to the amount ingested (in mg) multiplied by the bioavailability of the tablet preparation, which is 0.8.</li>
</ul>
<p><a href="#Table1">Table 1</a> gives dosage estimates in number of vials for adults and children who have ingested a single large dose of digoxin and for whom the approximate number of tablets or capsules is known. The dose of DigiFab<span class="Sup">®</span> (in number of vials) represented in Table 1 can be approximated using the following formula:</p>
<p><a name="F1"></a><span class="Bold">Formula 1</span></p>
<p>Dose             = <span class="Underline">total digitalis body load in mg</span><br>(in # of vials)    0.5 mg of digitalis bound/vial</p>
<a name="Table1"></a><table class="Noautorules" width="500">
<caption><span>Table 1 Approximate Dose of DigiFab<span class="Sup">®</span> for Reversal of a Single Large Digoxin <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">Overdose</span></span></caption>
<col width="50%">
<col width="50%">
<tfoot><tr><td colspan="4">
<span class="Sup">*</span> 0.25 mg tablets with 80% bioavailability or 0.2 mg capsules with 100% bioavailability </td></tr></tfoot>
<tbody class="Headless">
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><span class="Bold">Number of Digoxin Tablets<br>or Capsules Ingested*</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><span class="Bold">Dose of DigiFab<span class="Sup">®</span><br># of vials</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center">25</td>
<td class="Botrule Lrule Rrule Toprule" align="center">10</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center">50</td>
<td class="Botrule Lrule Rrule Toprule" align="center">20</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center">75</td>
<td class="Botrule Lrule Rrule Toprule" align="center">30</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center">100</td>
<td class="Botrule Lrule Rrule Toprule" align="center">40</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center">150</td>
<td class="Botrule Lrule Rrule Toprule" align="center">60</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center">200</td>
<td class="Botrule Lrule Rrule Toprule" align="center">80</td>
</tr>
</tbody>
</table>
<p>If, after several hours, toxicity is not adequately reversed, or appears to recur, additional administration of DigiFab<span class="Sup">®</span> at a dose guided by clinical judgment may be required.</p>
<p><span class="Bold">Calculations Based on Steady-State Serum Digoxin Concentrations:</span></p>
<p><span class="Bold">Adults</span></p>
<p><a href="#Table2">Table 2</a> gives dosage estimates in number of vials for adult patients for whom a steady-state serum digoxin concentration is known. The dose of DigiFab® (in number of vials) represented in Table 2 can be approximated using the following formula:</p>
<p><a name="F2"></a><span class="Bold">Formula 2 (see <a href="#Table2">Table 2</a>)</span></p>
<p>Dose            = <span class="Underline">(Serum digoxin concentration in ng/mL)(weight in kg)</span><br>(in # of vials)                                      100</p>
<a name="Table2"></a><table class="Noautorules" width="400">
<caption><span>Table 2 Adult Dose Estimate of DigiFab<span class="Sup">®</span> (in # of vials) from Steady-State Serum Digoxin Concentration </span></caption>
<col width="10%">
<col width="5%">
<col width="5%">
<col width="5%">
<col width="5%">
<col width="5%">
<col width="5%">
<col width="5%">
<tfoot><tr><td>v = vials</td></tr></tfoot>
<tbody class="Headless">
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><span class="Bold">Patient Weight<br>(kg)</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="7" valign="middle"><span class="Bold">Serum Digoxin Concentration (ng/mL)</span></td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="center"></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">1</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">2</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">4</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">8</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">12</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">16</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">20</span></td>
</tr>
<tr>
<td class="Lrule Rrule" align="center">40</td>
<td class="Botrule Lrule Rrule Toprule" align="center">0.5v</td>
<td class="Botrule Lrule Rrule Toprule" align="center">1v</td>
<td class="Botrule Lrule Rrule Toprule" align="center">2v</td>
<td class="Botrule Lrule Rrule Toprule" align="center">3v</td>
<td class="Botrule Lrule Rrule Toprule" align="center">5v</td>
<td class="Botrule Lrule Rrule Toprule" align="center">7v</td>
<td class="Botrule Lrule Rrule Toprule" align="center">8v</td>
</tr>
<tr>
<td class="Lrule Rrule" align="center">60</td>
<td class="Botrule Lrule Rrule Toprule" align="center">0.5v</td>
<td class="Botrule Lrule Rrule Toprule" align="center">1v</td>
<td class="Botrule Lrule Rrule Toprule" align="center">3v</td>
<td class="Botrule Lrule Rrule Toprule" align="center">5v</td>
<td class="Botrule Lrule Rrule Toprule" align="center">7v</td>
<td class="Botrule Lrule Rrule Toprule" align="center">10v</td>
<td class="Botrule Lrule Rrule Toprule" align="center">12v</td>
</tr>
<tr>
<td class="Lrule Rrule" align="center">70</td>
<td class="Botrule Lrule Rrule Toprule" align="center">1v</td>
<td class="Botrule Lrule Rrule Toprule" align="center">2v</td>
<td class="Botrule Lrule Rrule Toprule" align="center">3v</td>
<td class="Botrule Lrule Rrule Toprule" align="center">6v</td>
<td class="Botrule Lrule Rrule Toprule" align="center">9v</td>
<td class="Botrule Lrule Rrule Toprule" align="center">11v</td>
<td class="Botrule Lrule Rrule Toprule" align="center">14v</td>
</tr>
<tr>
<td class="Lrule Rrule" align="center">80</td>
<td class="Botrule Lrule Rrule Toprule" align="center">1v</td>
<td class="Botrule Lrule Rrule Toprule" align="center">2v</td>
<td class="Botrule Lrule Rrule Toprule" align="center">3v</td>
<td class="Botrule Lrule Rrule Toprule" align="center">7v</td>
<td class="Botrule Lrule Rrule Toprule" align="center">10v</td>
<td class="Botrule Lrule Rrule Toprule" align="center">13v</td>
<td class="Botrule Lrule Rrule Toprule" align="center">16v</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center">100</td>
<td class="Botrule Lrule Rrule Toprule" align="center">1v</td>
<td class="Botrule Lrule Rrule Toprule" align="center">2v</td>
<td class="Botrule Lrule Rrule Toprule" align="center">4v</td>
<td class="Botrule Lrule Rrule Toprule" align="center">8v</td>
<td class="Botrule Lrule Rrule Toprule" align="center">12v</td>
<td class="Botrule Lrule Rrule Toprule" align="center">16v</td>
<td class="Botrule Lrule Rrule Toprule" align="center">20v</td>
</tr>
</tbody>
</table>
<p><span class="Bold">Children:</span></p>
<ul class="Disc">
<li>
<a href="#Table3">Table 3</a> gives dosage estimates in milligrams for infants and small (&lt; 20 Kg) children based on the steady-state serum digoxin concentration.</li>
<li>The dose of DigiFab<span class="Sup">®</span> represented in <a href="#Table3">Table 3</a> can be estimated by multiplying the dose (in number of vials) calculated from Formula 2 by the amount of DigiFab<span class="Sup">®</span> contained in a vial (40 mg/vial) (see <a href="#F3">Formula 3</a>).</li>
<li> Administer smaller doses in children &lt; 20 Kg requiring doses &lt; 1mL with a tuberculin syringe after reconstituting 40 mg.</li>
<li>For very small doses, a reconstituted vial can be diluted with 36 mL of sterile isotonic saline to achieve a concentration of 1 mg/mL.</li>
</ul>
<p><a name="F3"></a><span class="Bold">Formula 3 (see <a href="#Table3">Table 3</a>)</span></p>
<p>Dose (in mg)   = (Dose in # of vials) (40 mg/vial) </p>
<a name="Table3"></a><table class="Noautorules" width="500">
<caption><span>Table 3 Infants and Small (&lt; 20 Kg) Children Dose Estimates of DigiFab<span class="Sup">®</span> (in mg) from Steady State Serum Digoxin Concentration </span></caption>
<col width="10%">
<col width="5%">
<col width="5%">
<col width="5%">
<col width="5%">
<col width="5%">
<col width="5%">
<col width="5%">
<tfoot><tr><td colspan="8">
<span class="Sup">*</span> dilution of reconstituted vial to 1 mg/mL may be desirable </td></tr></tfoot>
<tbody class="Headless">
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><span class="Bold">Patient Weight<br>(kg)</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="7" valign="middle"><span class="Bold">Serum Digoxin Concentration (ng/mL)</span></td>
</tr>
<tr>
<td class="Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">1</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">2</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">4</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">8</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">12</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">16</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">20</span></td>
</tr>
<tr>
<td class="Lrule Rrule" align="center">1</td>
<td class="Botrule Lrule Rrule Toprule" align="center">0.4 mg<span class="Sup">*</span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">1 mg<span class="Sup">*</span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">1.5 mg<span class="Sup">*</span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">3 mg<span class="Sup">*</span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">5 mg</td>
<td class="Botrule Lrule Rrule Toprule" align="center">6.5 mg</td>
<td class="Botrule Lrule Rrule Toprule" align="center">8 mg</td>
</tr>
<tr>
<td class="Lrule Rrule" align="center">3</td>
<td class="Botrule Lrule Rrule Toprule" align="center">1 mg<span class="Sup">*</span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">2.5 mg<span class="Sup">*</span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">5 mg</td>
<td class="Botrule Lrule Rrule Toprule" align="center">10mg</td>
<td class="Botrule Lrule Rrule Toprule" align="center">14 mg</td>
<td class="Botrule Lrule Rrule Toprule" align="center">19 mg</td>
<td class="Botrule Lrule Rrule Toprule" align="center">24 mg</td>
</tr>
<tr>
<td class="Lrule Rrule" align="center">5</td>
<td class="Botrule Lrule Rrule Toprule" align="center">2 mg<span class="Sup">*</span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">4 mg</td>
<td class="Botrule Lrule Rrule Toprule" align="center">8 mg</td>
<td class="Botrule Lrule Rrule Toprule" align="center">16 mg</td>
<td class="Botrule Lrule Rrule Toprule" align="center">24 mg</td>
<td class="Botrule Lrule Rrule Toprule" align="center">32 mg</td>
<td class="Botrule Lrule Rrule Toprule" align="center">40 mg</td>
</tr>
<tr>
<td class="Lrule Rrule" align="center">10</td>
<td class="Botrule Lrule Rrule Toprule" align="center">4 mg</td>
<td class="Botrule Lrule Rrule Toprule" align="center">8 mg</td>
<td class="Botrule Lrule Rrule Toprule" align="center">16 mg</td>
<td class="Botrule Lrule Rrule Toprule" align="center">32 mg</td>
<td class="Botrule Lrule Rrule Toprule" align="center">48 mg</td>
<td class="Botrule Lrule Rrule Toprule" align="center">64 mg</td>
<td class="Botrule Lrule Rrule Toprule" align="center">80 mg</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center">20</td>
<td class="Botrule Lrule Rrule Toprule" align="center">8 mg</td>
<td class="Botrule Lrule Rrule Toprule" align="center">16 mg</td>
<td class="Botrule Lrule Rrule Toprule" align="center">32 mg</td>
<td class="Botrule Lrule Rrule Toprule" align="center">64 mg</td>
<td class="Botrule Lrule Rrule Toprule" align="center">96 mg</td>
<td class="Botrule Lrule Rrule Toprule" align="center">128 mg</td>
<td class="Botrule Lrule Rrule Toprule" align="center">160 mg</td>
</tr>
</tbody>
</table>
<p><span class="Bold">Calculation Based on Steady-State Digitoxin Concentrations:</span></p>
<p>The dose of DigiFab<span class="Sup">®</span> for digitoxin toxicity can be approximated by using the following formula (which differs from Formula 2 in the denominator due to a 10-fold decrease in the volume of distribution of digitoxin as compared to digoxin).</p>
<p><a name="F4"></a><span class="Bold">Formula 4</span></p>
<p> Dose              = <span class="Underline">(Serum digitoxin concentration in ng/mL) (weight in kg)</span><br> (in # of vials)                                   1000 </p>
<p>If in any case, the dose estimated based on ingested amount (Formula 1) differs substantially from that calculated based on the serum digoxin or digitoxin concentration (Formulas 2 and 4), it may be preferable to use the higher dose estimate.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="AS022"></a><a name="section-2.2"></a><p></p>
<h2>2.2  Preparation and Administration</h2>
<ul class="Disc">
<li>Each vial contains 40 mg of digoxin immune Fab protein and  is intended for one time use only as it  contains no preservatives </li>
<li>Reconstitute each vial of DigiFab<span class="Sup">®</span> with 4 mL of Sterile Water for Injection USP and gently mix to provide a solution containing approximately 10 mg/mL of digoxin immune Fab protein.</li>
<li>Use the reconstituted product promptly. If not used immediately, store under refrigeration at 2° to 8°C (36° to 46°F) for up to 4 hours.  Add the reconstituted product to an appropriate volume of 0.9% sodium chloride for injection.</li>
<li>Visually inspect reconstituted vials for particulate matter and discoloration prior to administration, whenever solution and container permit.  Do not use if the solution is cloudy, turbid or if it contains particulates.</li>
<li>Administer DigiFab<span class="Sup">®</span> slowly as an intravenous infusion over at least 30 minutes. Stop the infusion if infusion rate-related anaphylactoid-type reactions occur, such as <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="314754" conceptname="Wheezing">wheezing</span>, or <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>.  The infusion can be re-started at a slower rate.  Give DigiFab<span class="Sup">®</span> by bolus injection, if <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span> is imminent.  An increased incidence of infusion-related reactions may be expected with bolus injection.</li>
<li>For infants and small children who may require very small doses, reconstitute the 40 mg vial as directed and administer undiluted using a tuberculin syringe. For very small doses, a reconstituted vial can be diluted with an additional 36 mL of isotonic saline to achieve a concentration of 1 mg/mL.</li>
</ul>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="AS030"></a><a name="section-3"></a><p></p>
<h1>3  DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">DigiFab<span class="Sup">®</span> is supplied as a sterile, purified, lyophilized preparation containing 40 mg of digoxin immune Fab protein per vial.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="AS040"></a><a name="section-4"></a><p></p>
<h1>4  CONTRAINDICATIONS</h1>
<p class="First">There are no known contraindications to the use of DigiFab<span class="Sup">®</span>.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="AS050"></a><a name="section-5"></a><p></p>
<h1>5  WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="AS051"></a><a name="section-5.1"></a><p></p>
<h2>5.1 General</h2>
<p class="First">Suicidal ingestion may result from more than one drug. Toxic effects of other drugs or poisons should not be overlooked, especially in cases where signs and symptoms of <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">digitalis toxicity</span> are not relieved by administration of DigiFab<span class="Sup">®</span>.</p>
<p>Rapid drop in serum potassium concentration may occur after treatment with DigiFab<span class="Sup">®</span>.   Monitor frequently, especially after the first several hours of DigiFab<span class="Sup">®</span> administration (see <a href="#AS054">5.4 Laboratory Tests</a>).</p>
<p>Patients with poor cardiac function may deteriorate secondary to the withdrawal of the inotropic action of digoxin by DigiFab<span class="Sup">®</span>. If needed, provide additional support by using other intravenous inotropes such as dopamine, dobutamine or vasodilators. However, take additional care not to aggravate the digitalis induced rhythm disturbances. Postpone re-digitalization, if possible, until the Fab fragments have been eliminated from the body, which may require several days, and patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span> may require a week or longer.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="AS052"></a><a name="section-5.2"></a><p></p>
<h2>5.2 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylaxis</span> and <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> are possible.  Carefully monitor all patients treated with DigiFab<span class="Sup">®</span> for signs and symptoms of an <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">acute allergic reaction</span> (e.g., <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span> with <span class="product-label-link" type="condition" conceptid="314754" conceptname="Wheezing">wheezing</span> or <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>, <span class="product-label-link" type="condition" conceptid="253321" conceptname="Stridor">stridor</span>, <span class="product-label-link" type="condition" conceptid="22350" conceptname="Edema of larynx">laryngeal edema</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>) and treat immediately with appropriate emergency medical care (e.g., oxygen, diphenhydramine, corticosteroids, volume expansion and airway management), if one occurs.</p>
<p>If an <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reaction</span> occurs during the infusion, terminate DigiFab<span class="Sup">®</span> administration at once and administer appropriate treatment. Balance the need for epinephrine against its potential risk in the setting of <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">digitalis toxicity</span>. Patients with known allergies to sheep protein are particularly at risk for an <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reaction</span>, as are individuals who have previously received intact ovine antibodies or ovine Fab.</p>
<p>Do not administer DigiFab<span class="Sup">®</span> to patients with a known history of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to papaya or papain unless the benefits outweigh the risks and appropriate management for <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reactions</span> is readily available.Prior treatment with digoxin-specific ovine immune Fab carries a theoretical risk of sensitization to ovine serum protein and possible diminution of the efficacy of the drug due to the presence of human antibodies against ovine Fab. To date, there have been no clinical reports of human anti-ovine immunoglobulin antibodies causing a reduction in binding of ovine digoxin immune Fab or neutralization response to ovine digoxin immune Fab.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="AS053"></a><a name="section-5.3"></a><p></p>
<h2>5.3 Use of DigiFab<span class="Sup">®</span> in <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal Failure</span></h2>
<p class="First">The elimination half-life of DigiFab<span class="Sup">®</span> in <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span> has not been clearly defined. Monitor patients with severe <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span> who receive DigiFab<span class="Sup">®</span> for <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">digitalis toxicity</span> for a prolonged period for possible recurrence of toxicity.</p>
<p>Monitoring of free (unbound) digoxin concentrations after the administration may be appropriate in order to establish recrudescent toxicity in <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span> patients.<span class="Sup">5</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="AS054"></a><a name="section-5.4"></a><p></p>
<h2>5.4 Laboratory Tests</h2>
<p class="First"><span class="Bold">DigiFab<span class="Sup">®</span> may interfere with digitalis immunoassay measurements. Thus, standard serum digoxin concentration measurements may be clinically misleading until the Fab fragments are eliminated from the body. </span>This may take several days or a week or more in patients with markedly <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. Therefore, serum samples for digoxin concentration should be obtained before DigiFab<span class="Sup">®</span> administration, if at all possible. Such measurements would establish the level of serum digoxin at the time of diagnosis of <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">digitalis intoxication</span>.</p>
<p>At least 6 to 8 hours are required for equilibration of digoxin between serum and tissue, so absorption of the last dose may continue from the intestine. Therefore, serum measurements may be difficult to interpret if samples are drawn soon after the last digitalis dose.</p>
<p>The total serum digoxin concentration may rise precipitously following administration of DigiFab<span class="Sup">®</span>, but this will be almost entirely bound to the Fab fragment and therefore not able to react with receptors in the body.</p>
<p>Patients should be closely monitored, including temperature, blood pressure, electrocardiogram, and potassium concentration, during and after administration of DigiFab<span class="Sup">®</span>. Digoxin causes a shift of potassium from inside to outside the cell, such that severe <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">intoxication</span> can cause a life-threatening elevation of serum potassium. This may lead to increased urinary excretion of potassium so that a patient may have <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> but a whole body deficit of potassium. When the toxic effects of digoxin are reversed by DigiFab<span class="Sup">®</span>, potassium shifts back into the cell with a resulting decline in serum potassium concentration. This <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> may develop rapidly. For these reasons, serum potassium concentration should be followed closely, especially during the first several hours after DigiFab<span class="Sup">®</span> administration. Cautious potassium supplementation should then be given when necessary.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="AS060"></a><a name="section-6"></a><p></p>
<h1>6  ADVERSE REACTIONS</h1>
<p class="First">The most common adverse reactions (&gt; 7%) related to DigiFab<span class="Sup">®</span> administration are worsening <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> (13%), <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> (13%) and worsening <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span> (7%).</p>
<div class="Section" data-sectionCode="42229-5">
<a name="AS061"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trial Experience</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.</p>
<p>In the clinical trials of DigiFab<span class="Sup">®</span>, 6 of 15 patients in the digoxin <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> study had a total of 17 adverse events. Three events occurred in one patient and consisted of the following: <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span>, bilateral <span class="product-label-link" type="condition" conceptid="254061" conceptname="Pleural effusion">pleural effusion</span> and <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>. The events were determined to be likely due to the loss of digoxin inotropic support in combination with the patient’s underlying medical condition. Of 8 healthy volunteers who received DigiFab<span class="Sup">®</span>, two experienced an adverse reaction that was considered to be related to DigiFab<span class="Sup">®</span>. The reactions were; one episode of <span class="product-label-link" type="condition" conceptid="318174" conceptname="Phlebitis">phlebitis</span> of the infusion-site vein and one episode of transient <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">postural hypotension</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="AS080"></a><a name="section-7"></a><p></p>
<h1>8  USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="AS081"></a><a name="section-7.1"></a><p></p>
<h2>8.1  Pregnancy</h2>
<p class="First"><span class="Italics">Pregnancy Category C. </span></p>
<p>Animal reproduction studies have not been conducted with DigiFab<span class="Sup">®</span>.  It is also not known whether DigiFab<span class="Sup">®</span> can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity.  DigiFab<span class="Sup">®</span> should be given to a pregnant woman only if clinically needed.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="AS083"></a><a name="section-7.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">It is not known whether DigiFab<span class="Sup">®</span> is excreted in human breast milk.  Because many drugs are excreted in human milk, caution should be exercised when DigiFab<span class="Sup">®</span> is administered to a nursing woman.  DigiFab<span class="Sup">®</span> should be given to nursing mothers only if clinically needed.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="AS084"></a><a name="section-7.3"></a><p></p>
<h2>8.4  Pediatric Use</h2>
<p class="First">Safety data in pediatric population is limited.  The pediatric dosing estimation is based on calculations for adult dosing.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="AS085"></a><a name="section-7.4"></a><p></p>
<h2>8.5  Geriatric Use</h2>
<p class="First">Specific studies in elderly patients have not been conducted. Of the 15 patients given DigiFab<span class="Sup">®</span> for <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">digoxin toxicity</span> in one clinical trial, the average age of all patients was 64 years and over half of the patients (8 of the 15) were 65 years of age or older. The oldest patient studied was 86 years old. There is no evidence that the efficacy of DigiFab<span class="Sup">®</span> would be altered due to advanced age alone; however, elderly patients have a higher chance of having <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span> and therefore should be monitored more closely for recurrent toxicity (See <a href="#AS053">5.3</a> Use of DigiFab<span class="Sup">®</span> in <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>).</p>
</div>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="AS110"></a><a name="section-8"></a><p></p>
<h1>11  DESCRIPTION</h1>
<p class="First">DigiFab<span class="Sup">®</span> [Digoxin Immune Fab (Ovine)] is a sterile, lyophilized preparation of digoxin-immune ovine Fab (monovalent) immunoglobulin fragments. These fragments are obtained from the blood of healthy sheep immunized with a digoxin derivative, digoxin-dicarboxymethoxylamine (DDMA), a digoxin analogue which contains the functionally essential cyclopentaperhydrophenanthrene: lactone ring moiety coupled to keyhole limpet hemocyanin (KLH).</p>
<p>The final product is prepared by isolating the immunoglobulin fraction of the ovine serum, digesting it with papain and isolating the digoxin-specific Fab fragments by affinity chromatography. These antibody fragments have a molecular weight of approximately 46,000 Da.</p>
<p>Each vial of DigiFab<span class="Sup">®</span>, which will bind approximately 0.5 mg digoxin, contains 40 mg of digoxin immune Fab, 75 mg (approx) of mannitol USP, and 2 mg (approx) sodium acetate USP as a buffering agent.</p>
<p>The product contains no preservatives and is intended for intravenous administration after reconstitution with 4 mL of Sterile Water for Injection USP.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="AS120"></a><a name="section-9"></a><p></p>
<h1>12  CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="AS121"></a><a name="section-9.1"></a><p></p>
<h2>12.1  Mechanism of Action</h2>
<p class="First">DigiFab<span class="Sup">®</span> has an affinity for digoxin in the range of 10<span class="Sup">9</span> to 10<span class="Sup">10</span> M<span class="Sup">-1</span>, which is greater than the affinity of digoxin for its sodium pump receptor, the presumed receptor for its therapeutic and toxic effects. When administered to the intoxicated patient, DigiFab<span class="Sup">®</span> binds to molecules of digoxin reducing free digoxin levels, which results in a shift in the equilibrium away from binding to the receptors, thereby reducing cardio-toxic effects. Fab-digoxin complexes are then cleared by the kidney and reticuloendothelial system.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="AS123"></a><a name="section-9.2"></a><p></p>
<h2>12.3  Pharmacokinetics</h2>
<p class="First">The pharmacokinetics and pharmacodynamics of DigiFab<span class="Sup">®</span> were assessed in a randomized and controlled study of DigiFab<span class="Sup">®</span> and Digibind<span class="Sup">®</span> (comparator Fab product for treatment of <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">digoxin toxicity</span>). Sixteen healthy subjects were given 1 mg of intravenous digoxin followed by an approximately equimolar neutralizing dose of either DigiFab<span class="Sup">®</span> (n=8) or Digibind (n=8). The objective of the pharmacokinetic and pharmacodynamic study was to compare parameters for DigiFab<span class="Sup">®</span> to those for Digibind.<span class="Sup">7</span>  The pharmacokinetics of both digoxin and Fab were determined and found to be similar for both products. The similar volumes of distribution (0.3 L/kg and 0.4 L/kg for DigiFab<span class="Sup">®</span> and Digibind, respectively) indicate considerable penetration from the circulation into the extracellular space and are consistent with previous reports of ovine Fab distribution, as are the elimination half-life values (15 hours and 23 hours for DigiFab<span class="Sup">®</span> and Digibind, respectively).<span class="Sup">8-12</span>  The elimination half-life of 15-20 hours in patients with normal renal function appears to be increased up to 10 fold in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, although volume of distribution remains unaffected.<span class="Sup">12</span></p>
<p>The primary outcome measure for this study was the serum level of free (unbound) digoxin. The results demonstrated that both products reduced the level of free digoxin in the serum to below the limit of assay quantitation for several hours after Fab administration. Cumulative urinary excretion of digoxin was comparable for both products and exceeded 40% of the administered dose by 24 hours. These results demonstrate that DigiFab<span class="Sup">®</span> and Digibind have equivalent pharmacodynamic effects on the digoxin parameters that are relevant to the treatment of <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">digoxin toxicity</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="AS130"></a><a name="section-10"></a><p></p>
<h1>13  NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="AS131"></a><a name="section-10.1"></a><p></p>
<h2>13.1  Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Animal carcinogenicity and reproduction studies have not been conducted with DigiFab.</p>
</div>
<div class="Section" data-sectionCode="34091-9">
<a name="AS132"></a><a name="section-10.2"></a><p></p>
<h2>13.2 Animal Toxicology and/or Pharmacology</h2>
<p class="First">No toxic effects were observed when DigiFab<span class="Sup">®</span> was administered to healthy male Sprague Dawley rats in equimolar doses sufficient to neutralize a 1 mg/kg dose of digoxin. In these studies, the physiologic changes produced by toxic serum concentrations of digoxin were ameliorated rapidly by the administration of DigiFab<span class="Sup">®</span> or comparator product Digibind.  Statistically equivalent responses were observed with both DigiFab<span class="Sup">®</span> and Digibind to the following variables: PTQ index, heart rate, mean arterial pressure, ventilation, arterial blood gases, and serum potassium concentrations.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="AS140"></a><a name="section-11"></a><p></p>
<h1>14  CLINICAL STUDIES</h1>
<p class="First">One prospective multi-center safety, efficacy and pharmacokinetic study in patients presenting with life-threatening <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">digoxin toxicity</span> was conducted in U.S. and Finland.</p>
<p>The objective of the study was to demonstrate safety, pharmacokinetics, and clinical response of DigiFab<span class="Sup">®</span> in patients. Results were compared to historical data on Digibind.  Fifteen patients received doses of DigiFab<span class="Sup">®</span> based on its theoretical binding capacity for digoxin, and based on the known amount of digoxin ingested or on blood concentrations of digoxin at the time of admission.</p>
<p>Serum free digoxin concentrations fell to undetectable concentrations in all patients following DigiFab<span class="Sup">®</span> administration. Ten of the 15 patients studied who had baseline ECG abnormalities improved within 4 hours after the DigiFab<span class="Sup">®</span> infusion. The remaining 5 patients who had baseline ECG abnormalities remained unchanged throughout the 24-hour assessment period, and in one case through the 30-day follow up period.  Seven out of the 15 patients (47%) studied had complete resolution of <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">digoxin toxicity</span> within 4 hours of DigiFab<span class="Sup">®</span> administration, and 14 patients (93%) were classified as having resolved their <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">digoxin toxicity</span> by 20 hours. In this study, where 2/15 patients had serum available for human anti-ovine antibody determination, there was no measurable immune response.</p>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="AS150"></a><a name="section-12"></a><p></p>
<h1>15  REFERENCES</h1>
<ol class="Arabic">
<li>Kojis FG. <span class="product-label-link" type="condition" conceptid="432522" conceptname="Transfusion reaction due to serum protein reaction">Serum sickness</span> and <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>: analysis of cases of 6,211 patients treated with horse serum for various <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>. Am J Dis Children 1942; 64:93-143, 313-350.</li>
<li>Quarre JP, Lecomte J, Lauwers D, Gilbert P, Thiriaux J. <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergy</span> to latex and papain. J <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergy</span> Clin Immunol 1995; 95(4):922.</li>
<li>Baur X, Chen Z, Rozynek P, Düser D, Raulf-Heimsoth M. Cross-reacting IgE antibodies recognizing latex allergens, including Hev b 1, as well as papain. <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergy</span> 1995; 50(7):604-609.</li>
<li>Wenger TL. Experience with digoxin immune fab (ovine) in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. Am J of Emer Med 1991; 9(supp. 1):21-23.</li>
<li>Valdes R, Jortani SA. Monitoring of unbound digoxin in patients with antidigoxin antigen-binding fragments: a model for the future ? Clin Chem 1998; 44(9):1883-1885.</li>
<li>Kirkpatrick CHG, Digibind<span class="Sup">®</span> Study Advisory Panel. Allergic histories and reactions of patients treated with digoxin immune fab (ovine) antibody. Am J of Emer Med 1991; 9(supp. 1):7-10.</li>
<li>Ward, SB, Sjostrom L, and Ujhelyi MR. Comparison of the pharmacokinetics and in vivo binding affinity of DigiTAb versus Digibind.Therapeutic Drug Monitoring 2000; 22:599-607.</li>
<li>Hickey AR, Wenger TL, Carpenter VP, et al. Digoxin immune fab therapy in the management of <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">digitalis intoxication</span>: safety and efficacy results of an observational surveillance study. J Am Coll Cardiol 1991; 17:590-598.</li>
<li>Antman EM, Wenger TL, Butler VP, Haber E, and Smith TW. Treatment of 150 cases of life threatening <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">digitalis intoxication</span> with digoxin-specific fab antibody fragments. Circulation 1990; 81:1744-1752.</li>
<li>Wenger TL, Butler VP Jr, Haber E, Smith TW. Treatment of 63 severely digitalis-toxic patients with digoxin-specific antibody fragments. J Am Coll Cardiol 1985; 5 (supp.):118A-123A.</li>
<li>Schaumann W, Kaufmann B, Neubert P, Smolarz A. Kinetics of the fab fragments of digoxin antibodies and of bound digoxin in patients with severe digoxin <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">intoxication</span>. Eur J Clin Pharmacol 1986; 30:527-533.</li>
<li>Ujhelyi MR, Robert S. Pharmacokinetic aspects of digoxin-specific fab therapy in the management of <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">digitalis toxicity</span>. Clin Pharmacokinet 1995; 28(6):483-493.</li>
</ol>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="AS160"></a><a name="section-13"></a><p></p>
<h1>16  HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">DigiFab is supplied as a carton that contains 1 vial of product (diluent not included).</p>
<ul>
<li>NDC 50633-120-11</li>
<li>Store at 2° to 8°C (36° to 46°F).</li>
<li>Do not freeze.</li>
<li>Use within 4 hours after reconstitution.</li>
</ul>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="AS170"></a><a name="section-14"></a><p></p>
<h1>17  PATIENT COUNSELING INFORMATION</h1>
<p class="First">Advise patients to contact their physician immediately if they experience any signs and symptoms of delayed <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> or <span class="product-label-link" type="condition" conceptid="432522" conceptname="Transfusion reaction due to serum protein reaction">serum sickness</span> (e.g., <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>) after hospital discharge.</p>
<p>Manufactured for <br>and distributed by:</p>
<p>BTG International Inc. <br>West Conshohocken, PA 19428</p>
<p>U.S. License No. 1861</p>
<p>DigiFab<span class="Sup">®</span> is a registered trademark of BTG International Inc.<br>BTG and the BTG roundel logo are registered trademarks of BTG International Ltd.</p>
<p>P12011D-1       August 2014</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="MM100"></a><a name="section-15"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - NDC: 50633-120-11 - 40 mg Vial Label</h1>
<p class="First"><img alt="Vial Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c05ee6a5-c98b-45f4-83fd-40781639d653&amp;name=digifab-01.jpg"></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="MM200"></a><a name="section-16"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - NDC: 50633-120-11 - 40 mg Carton Label</h1>
<p class="First"><img alt="Carton Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c05ee6a5-c98b-45f4-83fd-40781639d653&amp;name=digifab-02.jpg"></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>DIGIFAB 		
					</strong><br><span class="contentTableReg">ovine digoxin immune fab injection, powder, for solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:50633-120</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>OVINE DIGOXIN IMMUNE FAB</strong> (DIGOXIN) </td>
<td class="formItem">OVINE DIGOXIN IMMUNE FAB</td>
<td class="formItem">40 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MANNITOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM ACETATE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:50633-120-11</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">1  in 1 VIAL, GLASS; Combination Product Type = C102839</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">BLA</td>
<td class="formItem">BLA103910</td>
<td class="formItem">08/31/2001</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>BTG International Inc.
							(617382395)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Cangene bioPhamra Inc.</td>
<td class="formItem"></td>
<td class="formItem">050783398</td>
<td class="formItem">MANUFACTURE(50633-120)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Protherics UK Limited</td>
<td class="formItem"></td>
<td class="formItem">536591589</td>
<td class="formItem">API MANUFACTURE(50633-120)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 7/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>cbd96032-2c1e-486e-922e-d2e6f648fdb0</div>
<div>Set id: c05ee6a5-c98b-45f4-83fd-40781639d653</div>
<div>Version: 1</div>
<div>Effective Time: 20150702</div>
</div>
</div> <div class="DistributorName">BTG International Inc.</div></p>
</body></html>
